Ann: POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV, page-262

Without the data, one cannot conclude at all. However, I agree the market release was worded poorly. It's more likely it's reflective of the dropout rates of the TDF FTC DTG published previously. The market release says there were "no deaths or drug-related serious adverse events". The dropout in question probably had an upset stomach or some other non serious side effect the participant could not handle. And.. we can't conclude it was the cART or the Bit225 or both. We only know that there was no change in safety and tolerability seen in previous studies.

Lux, do you feel a faster drop in viral numbers is worth shouting about? It could make a huge difference for those commencing cART. Less virus numbers by the termination of phase 2 decay = fewer or no latent reservoirs = possible higher cure rate for acute infection (Rx commenced within 3 days) and better long-term health outcomes for all others.